We are live on ! Find out more
KLDO

Kaleido Biosciences, Inc. Common Stock
KLDO

Delisted

KLDO was delisted on the 14th of April, 2022.

Back to rankings

45 hedge funds and large institutions have $122M invested in Kaleido Biosciences, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 4

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

10% more funds holding

Funds holding: 41 → 45 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

32% less capital invested

Capital invested by funds: $180M → $122M (-$58.3M)

Holders
45
Holders Change
+4
Holders Change %
+9.76%
% of All Funds
0.89%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
8
Increased
24
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.63M
2
BCM
Bridgeway Capital Management
Texas
+$805K
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$771K
4
Goldman Sachs
Goldman Sachs
New York
+$710K
5
Bank of America
Bank of America
North Carolina
+$371K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$2.54M
2
RSCM
Rock Springs Capital Management
Maryland
-$753K
3
KA
Kerrisdale Advisers
Florida
-$546K
4
BCM
Barometer Capital Management
Ontario, Canada
-$226K
5
Millennium Management
Millennium Management
New York
-$161K
Name Holding Trade Value Shares
Change 		Change in
Stake
First Trust Advisors
26
First Trust Advisors
Illinois
$60K -$902 -142 -1%
Barclays
27
Barclays
United Kingdom
$57K +$56.4K +8,876 +357%
Wells Fargo
28
Wells Fargo
California
$56K +$3.18K +500 +5%
New York State Common Retirement Fund
29
New York State Common Retirement Fund
New York
$45K – – –
TRCT
30
Tower Research Capital (TRC)
New York
$44K +$55.7K +8,772 New
AIG
31
American International Group
New York
$36K +$25K +3,928 +123%
JP Morgan Chase
32
JP Morgan Chase
New York
$19K +$13K +2,053 +124%
Deutsche Bank
33
Deutsche Bank
Germany
$19K +$15.8K +2,486 +179%
Citigroup
34
Citigroup
New York
$12K +$10.2K +1,599 +188%
Legal & General Group
35
Legal & General Group
United Kingdom
$11K +$7.92K +1,247 +144%
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$8.29K +$8.91K +1,402 +561%
Bank of Montreal
37
Bank of Montreal
Ontario, Canada
$7K +$5.61K +883 +160%
SO
38
STRS Ohio
Ohio
$6K – – –
US Bancorp
39
US Bancorp
Minnesota
$3K – – –
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$3K +$3.16K +497 +492%
FDCDDQ
41
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.51K +$3.18K +500 New
AIP
42
Ameritas Investment Partners
Nebraska
$2K – – –
TFA
43
Toth Financial Advisory
Virginia
$1K – – –
MF
44
Manchester Financial
California
$1K +$1.27K +200 New
VFA
45
Valeo Financial Advisors
Indiana
$1K +$1.27K +200 New
RSCM
46
Rock Springs Capital Management
Maryland
– -$753K -100,050 Closed
KA
47
Kerrisdale Advisers
Florida
– -$546K -72,480 Closed
BCM
48
Barometer Capital Management
Ontario, Canada
– -$226K -30,000 Closed
Millennium Management
49
Millennium Management
New York
– -$161K -21,406 Closed
1
2

KLDO Hedge Fund Activity: Q4 2019 in Review

45 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q4 2019, worth a combined $122M — down 32% from $180M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new KLDO positions and 4 closed out — a net gain of 4 holders — while 24 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $1.63M. The largest seller was Artal Group, cutting an estimated $2.54M.

  • 45 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q4 2019, up from 41 in Q3 2019.
  • Funds reported $122M of Kaleido Biosciences, Inc. Common Stock stock for Q4 2019, down 32% quarter-over-quarter.
  • 8 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q4 2019 and 4 closed out, a net change of +4 holders.
  • The largest Kaleido Biosciences, Inc. Common Stock buyer in Q4 2019 was BlackRock, an estimated $1.63M added.
  • The largest Kaleido Biosciences, Inc. Common Stock seller in Q4 2019 was Artal Group, an estimated $2.54M sold.

Based on aggregated 13F filings for Q4 2019.